Int. VTE & Cancer Guidelines

Android App Analysis and Review: Int. VTE & Cancer Guidelines, Developed by Wizaxe. Listed in Medical Category. Current Version Is 2.0.0, Updated On 17/05/2023 . According to users reviews on Google Play: Int. VTE & Cancer Guidelines. Achieved Over 4 thousand Installs. Int. VTE & Cancer Guidelines Currently Has 10 Reviews, Average Rating 4.9 Stars

This application is available in English, French, Spanish, Portuguese, and Russian. The language of the app will be determined by the language setting of the user’s smartphone.

Based on international guidelines published in 2019, which was developed with methodological support from the Institut National du Cancer (INCa) in France and endorsed by the International Society on Thrombosis and Hemostasis (ISTH), this app is a practical step-by-step guide for the prophylaxis and treatment of venous thromboembolism (VTE: deep vein thrombosis (DVT), pulmonary embolism (PE), catheter-related thrombosis) in patients with cancer, including:
• Prophylaxis in hospitalized and ambulatory patients
• Recommendations for the treatment of both non-catheter and catheter-related VTE
• Specific recommendations related to various cancer and treatment types
• Recommendations for initial, short-term, and long-term treatment

This treatment algorithm for anticoagulant use (low molecular weight heparins (LMWH), direct oral anticoagulants (DOAC, NOAC), and vitamin K antagonists (VKA)) is intended for physicians and other healthcare professionals treating patients with cancer. It should not replace clinical judgement. It is based on clinical practice guidelines published in 2019:

Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J, and the International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019. September 03, 2019 DOI: https://doi.org/10.1016/S1470-2045(19)30336-5

While these guidelines rely on the best available evidence at the time of publication, the clinician is advised to use clinical judgement when making decisions about prophylaxis and treatment of cancer-associated thrombosis (CAT).

APP AUTHORS / STEERING COMMITTEE
Professor Dominique Farge (France) (Co-Chair)
Professor James Douketis (Canada) (Co-Chair)
Dr Corinne Frère (France)
Dr Jean Marie Connors (United States of America)
Dr C Cihan Ay (Austria)
Professor Alok A Khorana (United States of America)
Professor Andres Munoz (Spain)
Professor Benjamin Brenner (Israel)
Professor Ajay Kakkar (United Kingdom)
Dr Hanadi Rafii (France)
Dr Susan Solymoss (Canada)
Dr Dialina Brilhante (Portugal)
Professor Manuel Monreal (Spain)
Professor Henri Bounameaux (Switzerland)
Professor Ingrid Pabinger (Austria)

ABOUT ITAC-CME
The International Initiative on Thrombosis and Cancer (ITAC-CME) is the international section of the Groupe Francophone Thrombose et Cancer (GFTC). A multidisciplinary group, the members of ITAC-CME are clinicians and researchers from across the globe, led by a core group of GFTC members. Through education of physicians, nurses, and allied health professionals, ITAC-CME is committed to disseminating relevant and peer-reviewed prophylaxis and treatment guidelines for VTE in cancer that will help to reduce a substantial economic burden on health care systems and improve the lives of millions of patients worldwide.

Read more